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Abstract
The introduction of antigen into the anterior chamber (AC) of the eye induces the production of
antigen-speciﬁc splenic CD8
1 regulatory T cells (AC-SPL cells) that suppress a delayed-type
hypersensitivity (DTH) reaction in immunized mice. Because the generation of these regulatory T cells
is also induced by exposure to transforming growth factor (TGF)-b and antigen or F4/80
1 cells
exposed to TGF-b and antigen in vitro, we investigated (i) whether these cells are produced in
dominant negative receptor for transforming growth factor b receptor type II (dnTGFbRII) or Cbl-b
2/2
mice whose T cells are resistant to TGF-b, (ii) whether DTH is suppressed by wild type (WT) CD8
1 AC-
SPL cells in Cbl-b
2/2 and dnTGFbRII mice and (iii) the effect of antibodies to TGF-b on the
suppression of DTH by CD8
1 AC-SPL cells. DnTGFbRII immunized and Cbl-b
2/2 mice produced
splenic CD8
1 regulatory cells after the intracameral injection of antigen and immunization. The
suppression of a DTH reaction by CD8
1 AC-SPL cells in WT mice was blocked by the local inclusion of
antibodies to TGF-b when WT splenic CD8
1 AC-SPL cells were injected into the DTH reaction site.
Moreover, the DTH reaction in immunized dnTGFbRII and Cbl-b
2/2 mice was not suppressed by the
transfer of WT CD8
1 AC-SPL cells to the site challenged with antigen. In aggregate, these
observations suggest that T cell sensitivity to TGF-b is not an obligate requirement for the in vivo
induction of CD8
1 AC-SPL T cells but the suppression of an in vivo DTH reaction by CD8
1 AC-SPL
cells is dependent on TGF-b.
Introduction
The antigen-speciﬁc suppression of Tcells to self and non-self
antigens in Th1 and Th2 immune responses is effected by
CD8
+ regulatory T cells that are distinct from CD8
+ cytotoxic
T cells (1–6). In addition to induction, CD8
+ regulatory T cells,
unlike CD4
+,C D 2 5
+, Foxp3
+ regulatory T cells, suppress im-
munized T cells (7). Moreover, the immunosuppressive activity
of CD8
+ regulatory T cells is detected after an immune re-
sponse to the antigen (1, 4), suggesting that antigen-speciﬁc
CD8
+ regulatory T cells are induced and/or ampliﬁed during
an immune response but the requirements and/or mecha-
nisms of the activation of these cells in vivo are not clear.
CD8
+ regulatory T cells are induced by the injection of anti-
gen into the anterior chamber (AC) of an eye [AC-SPL cells
(6, 8–12)] or in vitro by the ligation of 4-1BB (13, 14), trans-
forming growth factor (TGF)-b (15) or TGF-b, antigen-pulsed
F4/80
+ cells (16). The immunosuppressive properties of TGF-b
(17) suggest that this cytokine could be a suppressive mecha-
nism used in vivo by CD8
+ regulatory T cells. Accordingly,
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the immunosuppression mediated by CD8
+ regulatory T cells.
In the current studies, we investigated requirements for
T cell sensitivity to TGF-b for the generation in vivo of splenic
CD8
+ regulatory T cells induced by the injection of antigen
into the AC by using two genetically engineered strains of
mice, dominant negative receptor for transforming growth
factor b receptor type II (dnTGFbRII) or Cbl-b
/, resistant
to TGF-b. In the second strain, the E3 ubiquitin ligase Cbl-b has
been speciﬁcally deleted [Cbl-b
/ mice (18, 19)]. Cbl-b,
a member of the Cbl/Sli family of molecular adaptors and
a ubiquitin ligase, has been shown to negatively regulate
CD28-dependent T cell activation. Recently, we reported that
Cbl-b
/ T cells, though not constitutively activated, are
resistant to the inhibitory effects of TGF-b (20, 21). Cbl-b
/
T cells display increased proliferation after TCR stimulation
and produce increased amounts of IL-2, but not IFN-b or
tumor necrosis factor-a.C b l - b
/ mice have T cells that are
independent of CD28 co-stimulation, in that they do not
require CD28 engagement for IL-2 production and proliferation
(18, 19). Moreover, Cbl-b
/ mice develop spontaneous auto-
immunity characterized by auto-antibody production, inﬁltra-
tion of activated T and B lymphocytes into multiple organs,
and parenchymal damage and are highly susceptible to
experimental autoimmune encephalomyelitis (18, 19). In the
second TGF-b-resistant strain, mice transgenically express
ad n T G F bRII in CD4
+ and CD8
+ T cells (22). This dominant
negative TGF-b receptor prevents TGF-b from signaling nor-
mally in T cells and T cells from dnTGFbRII mice respond well
to antigen but do not respond to TGF-b. A signiﬁcant percent-
age of the T cells from dnTGFbRII mice show evidence of prior
activation in terms of CD44 expression (22).
We show that (i) dnTGFbRII and Cbl-b
/ mice that re-
ceived an intracameral injection of antigen produce CD8
+
AC-SPL cells that suppress a DTH reaction when transferred
to wild-type (WT) recipients; (ii) The DTH reaction cannot be
suppressed in immunized dnTGFbRII and Cbl-b
/ recipi-
ents by transferred WT CD8
+ AC-SPL cells. (iii) Antibodies
to TGF-b inhibit the local in vivo suppression of a DTH reac-
tion by CD8
+ regulatory spleen cells induced by the injection
of antigen into the AC. These results suggest that sensitivity
to TGF-b by T cells is not obligate for the in vivo induction of
CD8
+ AC-SPL cells induced via the AC but TGF-b is likely
a suppressive mechanism utilized by CD8
+ AC-SPL cells.
Methods
Mice
Female or male C57BL/6 mice 8–10 weeks old were pur-
chased from Charles River/NCI Laboratories (Wilmington,
MA, USA). Cbl-b-deﬁcient mice (18, 19) on a C57BL/6 back-
ground, a gift from Dr H. Gu (National Institutes of Health,
Bethesda, MD, USA) are bred in our facilities under speciﬁc,
pathogen-free conditions. DnTGFbRII mice [CD4-dnTGFbRII
(22)] derived from Dr Flavell’s colonies at Yale University are
bred in our facilities under speciﬁc, pathogen-free condi-
tions. All mice are maintained in the Center for Laboratory
Animal Care of the University of Connecticut Health Center.
All work with animals was approved previously by the Uni-
versity of Connecticut Health Center Animal Care Committee
(ACC2007-380, ACC2007-379). All animals were treated
according to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Antigens/immunization
Trinitrophenol–BSA 2,4,6, Trinitrobenzene sulphonic acid
(TNP), BSA and ovalbumin (OVA) were purchased from Sigma
Chemical Co. (St Louis, MO, USA). TNP–BSA was prepared
as described by Li et al. (10). Picryl chloride (PCl), 2-chloro-
1,3,5-trinitorobenzene [the antigenic equivalent of TNP used
to elicit contact sensitivity (CS)] was purchased as 2-chloro-
5-trypthtane from Chemical Alta Ltd (Edmonton, Alberta,
Canada). Mice were immunized by a single subcutaneous in-
jection of 200 lg TNP–BSA in 50 ll CFA (Sigma–Aldrich, St
Louis, MO, USA). In general, the mice were challenged to
induce CS to TNP 7–9 days after the mice were immunized.
OVA Mice received s.c. 200 lg OVA in 50 ll CFA to a ﬂank.
Induction of DTH reaction
A CS reaction to TNP in TNP–BSA-sensitized or naive mice was
induced by the epicutaneous application of 15 ll1 %P C l )i n
acetone:olive oil (4:1) to a footpad (10). A DTH reaction (we
deﬁne the DTH reaction as the swelling induced by the appli-
cation of antigen to an immunized recipient to distinguish the
DTH reaction from the initiation of a Th1 response) to OVA
was induced by an intra-dermal injection of 50 lgO V Ai n
30 ll PBS (pH 7.2). The DTH response was usually measured
approximately 24–48 h after the application of PCl or injection
of OVA by measuring footpad thickness with an engineer’s
digital micrometer (Mitatoyo, Tokyo, Japan). Before challenge,
mice were anesthetized with ketamine (75 mg kg
1)/xylazine
(15 mg kg
1) and the thickness of each footpad was mea-
sured. One footpad was then challenged with antigen and
the other with vehicle only. Twenty-four hours later the mice
were anesthetized with ketamine/xylazine and the thickness
of each footpad was measured. The thickness of each foot-
pad before the application of PCl was subtracted from that of
the thickness 24 h after the application of PCl. The increase
in the thickness of the footpad deﬁned as swelling was com-
puted as the difference in the increase in micrometers be-
tween the 24 h and 0 h measurement of the thickness of the
challenged footpad minus that of the unchallenged footpad.
Injection of antigen into the AC (intracameral injection)
Mice were anesthetized with ketamine/xylazine (75 mg kg
1)/
xylazine (15 mg kg
1) and, under a dissecting microscope,
;3 ll PBS containing 4 lg TNP–BSA or 50 lg OVA was
injected into the AC. A 32g needle attached to a cannula at-
tached to a manually controlled Hamilton syringe (Stoelting
Co., Wood Dale, IL, USA) was inserted into the AC. The
mice recovered ;30 min after the injection; they exhibited
no distress and began eating and drinking normally. Seven
days after the intracameral injection of antigen, mice were
immunized with TNP–BSA as described (9, 10).
Preparation of splenic AC-induced regulatory cells (AC-SPL
cells)
Fourteen days after receiving an injection of TNP–BSA into
the AC and 7 days after the AC-injected mice were
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+ Tregimmunized, spleens were removed from the mice, pooled,
diced and expressed through a 40-mm nylon mesh (BD Fal-
con, Bedford, MA, USA) with a 1-ml syringe plunger into
PBS. The cells were washed 23 and suspended in PBS at
1 3 10
8 ml
1. The cell suspension was washed with PBS
and centrifuged at 200 3 g for 6–8 min. BD Pharm Lyse
(BD Biosciences, San Jose, CA, USA) was used for lysing
the erythrocytes according to the manufacturer’s protocol.
The cells were then washed twice with PBS and re-sus-
pended in PBS. CD8
+ and CD8
 spleen cells were prepared
by washing splenocytes two times with PBS and re-sus-
pending the cells in BD
TM IMag separation buffer (BD Bio-
sciences, Rockville, MD, USA). The spleen cells were
separated by immunomagnetic beads into CD8
+ and CD8

populations with a BD
TM CD8 T lymphocyte enrichment set
(BD Biosciences) according to the manufacturer’s protocol.
Enrichment of the cells was assessed by ﬂow cytometry
and found to be >87–92% pure CD8
+ T cells. The CD8

fractions showed <3% CD8
+ T cells (data not shown).
Local transfer of suppression (LTS)
AC-SPL cells were assayed for the suppression of the DTH
reaction by the LTS assay (10). Spleen cells were counted
with a Coulter counter and unless otherwise speciﬁed
10 000 or 25 000 cells in 40 ll PBS were injected subcuta-
neously into the footpad of immunized mice immediately fol-
lowing epicutaneous challenge with PCl. Swelling was
measured 24 h later.
The use of anti-TGF-b antibodies in the LTS was per-
formed by admixing AC-SPL cells from donors that received
an intracameral injection of antigen (1 3 10
6 ml
1 PBS) with
monoclonal anti-TGF-b (TGF-b1,2,3) IgG1 antibody (MAB
#1835, R&D Systems, Minneapolis, MN, USA) or isotype
control MOPC 21 IgG (Sigma, St Louis, MO, USA) so that
40 ll contained 15 lg antibody or MOPC 21 isotype control.
The cells were held at 4 C for 30 min and then injected intra-
dermally into the footpad of sensitized recipients immedi-
ately after the footpad was challenged with antigen. Some
immunized mice received an injection of anti-TGF-b antibody
only after challenge.
Statistics
Statistical signiﬁcance was calculated by one-way analysis
of variance. P-values were determined by the Student–
Neuman–Keuls test.
Results
Antigen-speciﬁc local suppression of the DTH reaction by
CD8
+ AC-SPL cells
To conﬁrm and demonstrate the phenotype of AC-SPL cells
that suppress locally the DTH reaction in the LTS, graded
numbers of CD8
+, CD8
 or unseparated AC-SPL cells from
donors that received an intracameral injection of TNP–BSA
were injected into the footpads of TNP–BSA-immunized mice
immediately after the footpads were challenged with epicu-
taneous PCl. The swelling reaction in the footpads was elimi-
nated or reduced signiﬁcantly in the recipients of unseparated
or CD8
+ but not CD8
 AC-SPL cells (Fig. 1). The enrichment
for CD8
+ regulatory spleen cells is shown by the suppres-
sion of PCl-induced swelling by limiting numbers (1, 250) of
CD8
+ AC-SPL cells while that number of unseparated AC-
SPL cells did not suppress swelling signiﬁcantly. CD8
+ AC-
SPL cells recovered from donors that received intracameral
injections of TNP–BSA or OVA were assayed for the ability
to suppress the DTH reaction when injected into the foot-
pads of mice immunized to TNP–BSA or OVA after the foot-
pad was challenged with PCl or OVA. As shown in Fig. 2,
CD8
+ spleen cells recovered from donors receiving intra-
cameral TNP–BSA suppressed the swelling reaction of
TNP–BSA-immunized mice challenged with PCl but not that
of OVA-sensitized mice challenged with OVA. Conversely,
AC-SPL cells from mice receiving intracameral OVA suppress
the OVA-induced swelling in OVA-immunized mice but not
PCl-induced swelling in TNP–BSA-immunized mice (data not
shown). Therefore, the results in Figs 1 and 2 document fur-
ther that the local, antigen-speciﬁc suppression of the DTH
reaction in immunized recipients by transferred AC-SPL cells
in the LTS is due to CD8
+ regulatory T cells.
AC-SPL CD8
+ regulatory cells are produced by dnTGFbRII
mice or Cbl-b
/ mice
To determine whether sensitivity to TGF-b by T cells is re-
quired by the T cells in vivo to generate splenic CD8
+ regula-
tory cells after the intracameral injection of antigen, we
investigated whether CD8
+ regulatory T cells are generated
in dnTGFbRII and Cbl-b
/ mice after these mice received
an injection of TNP–BSA into the AC. WT, dnTGFbRII or
Cbl-b
/ mice received an intracameral injection of
TNP–BSA. One week later, the mice were immunized with
TNP–BSA and 1 week after immunizing, spleen cells were
recovered from these mice and injected into the footpads of
TNP–BSA-sensitized WT mice immediately after the footpads
were challenged with epicutaneous PCl. Fig. 3(A and B)
demonstrate that the injection of unseparated WT but not un-
separated Cbl-b
/ or dnTGFbRII-derived AC-SPL cells into
the footpad at a challenge site at the time of challenge
resulted in a signiﬁcant reduction in footpad swelling in the
immunized recipient. However, swelling was suppressed in
the footpads of the recipients of Cbl-b
/ or dnTGFbRII-
derived CD8
+ AC-SPL cells despite the fact that unsepa-
rated Cbl-b
/ or dnTGFbRII-derived CD8
+ AC-SPL did not
suppress the DTH reaction. Moreover, the intracameral injec-
tion of TNP–BSA into Cbl-b
/ or dnTGFbRII mice induced
the production of peripheral blood mononuclear cells or thy-
mocytes that induce splenic CD8
+ AC-SPL cells (data not
shown).
WT CD8
+ spleen cells from mice receiving intracameral
antigen do not suppress DTH in TGF-b-resistant Cbl-b
/ or
dnTGFbRII mice
Because unseparated AC-SPL cells from TGF-bRII or
Cbl-b
/ mice did not suppress the DTH reaction but CD8
+
AC-SPL cells did suppress the DTH reaction when trans-
ferred to immunized recipients, we reasoned that the AC-SPL
cells from TGR-bRII or Cbl-b
/ mice might contain T cells
resistant to suppression effected by TGF-b. These cells
could transfer a hypersensitivity reaction to the recipient mice.
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+ Treg 569To investigate this hypothesis, we determined whether the
DTH reaction was suppressed by AC-SPL cells in mice re-
sistant to TGF-b. Because Cbl-b
/ mice lacking the ubiqui-
tin ligase Cbl-b are resistant to the immunosuppressive
effects of TGF-b (20, 21), spleen cells from WT donors that
received intracameral TNP–BSA were injected into a footpad
of TNP–BSA-immunized Cbl-b
/ or WT mice immediately
after the mice were challenged with an epicutaneous appli-
cation of PCl. Swelling was measured 24 h later. Immunized
Cbl-b
/ and WT mice both showed robust a DTH reaction
when challenged with PCl. WT spleen cells suppressed the
DTH response of WT mice to naive levels but, in contrast,
the DTH response of Cbl-b
/ mice receiving WT spleen
cells was not suppressed (Fig. 4).
To more speciﬁcally test the hypothesis that sensitivity to
TGF-b is required for the suppression of DTH in vivo by
Fig. 1. CD8
+ AC-SPL cells suppress DTH in WT mice in the LTS. WT
(C57BL/6) mice received an injection of TNP–BSA into the AC. One
week later, these mice were immunized with TNP–BSA and CFA.
Seven days later, the spleens were recovered from the AC-injected
mice, pooled and a spleen cell suspension was prepared (AC-SPL
cells). Spleen cells were separated into CD8
+ and CD8
 cells by
immunomagnetic beads; 1.25 3 10
3 to 2.5 3 10
4 unseparated
(UNSEP), CD8
+ or CD8
 AC-SPL cells were injected into the footpads
of TNP–BSA-immunized (IMM) or naive C57BL/6 mice immediately
after the footpads were challenged with epicutaneous PCl. The
thickness of the footpads before and 24 h after challenge was
measured to compute the swelling of the footpad. Data represents
one of three experiments with similar results and is the mean 6 SEM
swelling of ﬁve mice per group. *P < 0.01.
Fig. 2. Antigen-speciﬁc suppression of DTH in the LTS by CD8
+ AC-
SPL cells. CD8
+ AC-SPL cells recovered from mice that received an
intracameral injection of TNP–BSA were then immunized with TNP–
BSA and injected into the footpads of TNP–BSA-immunized or OVA-
immunized mice immediately after the footpad of the immunized mice
was challenged with epicutaneous PCl or intra-dermal OVA, re-
spectively. Swelling was measured 24 h after challenge. Data are the
mean 6 SEM for the results obtained in two experiments with eight
mice per group. *P < 0.01.
Fig. 3. Intracameral injection of antigen induces CD8
+ regulatory
T cells in dnTGFbRII mice and Cbl-b
/ mice. (A) One week after
dnTGFbRII mice received an intracameral injection of TNP–BSA, the
mice were immunized with TNP–BSA and CFA. One week later,
spleens were recovered, spleen cell suspensions prepared and
separated into CD8
+ and CD8
 populations by immunomagnetic
beads. IMM, immunized WT recipients received 25 000 unseparated
AC-SPL cells (UNSEP) or separated AC-SPL cells. NAIVE, non-
immune mice. Swelling is the mean 6 SEM of data obtained in three
experiments of 9–10 mice per group. *P < 0.01. (B) One week later,
Cbl-b
/ mice received an intracameral injection of TNP–BSA, the
mice were immunized with TNP–BSA and CFA. One week after
immunization, spleens were recovered and spleen cell suspensions
prepared and separated with immunomagnetic beads into CD8
+ and
CD8
 populations. TNP–BSA-immunized recipient WT mice received
an intradermal injection of 10 000 unseparated (UNSEP), CD8
+ or
CD8
 AC-SPL cells into the challenged footpad immediately after
challenge. Swelling was measured 24 h after challenge with
epicutaneous PCl. Data are the mean and SEM of two experiments,
six to eight mice per group. *P < 0.05.
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received an intracameral injection of TNP–BSA were tested
for suppressive ability in the LTS in WT or dnTGFbRII mice.
T cells in dnTGFbRII mice are largely resistant to the effects
of TGF-b as a result of the T cell-speciﬁc expression of
a dominant negative TGF-b receptor II (22). Although the
PCl-induced footpad swelling responses were generally
smaller in this series of experiments, the DTH responses
were suppressed in the WT mice receiving the WT regulatory
spleen cells while the responses were not signiﬁcantly sup-
pressed in the dnTGFbRII mice receiving the WT regulatory
spleen cells (Fig. 5).
The suppression of the DTH reaction by CD8
+ AC-SPL cells is
inhibited by antibodies to TGF-b
Because CD8
+ T cells in the spleens of mice that received
an intracameral injection of antigen produce TGF-b (12, 23)
and T cells resistant to TGF-b are resistant to suppression
mediated by CD8
+ AC-SPL cells, we reasoned that the
DTH-suppressive mechanism of the CD8
+ AC-SPL cells may
be dependent on TGF-b. To test this hypothesis, antibodies
that recognize TGF-b 1–3 were included in the inoculum of
C57Bl/6 AC-SPL cells injected into footpads of TNP–BSA-
immunized WT mice immediately after the challenge with
epicutaneous PCl. The swelling of the footpads that received
AC-SPL cells and control IgG1 antibody (MOPC 21) was
suppressed signiﬁcantly, i.e. ;75% less swelling than that
of challenged, immunized mice that did not receive regula-
tory spleen cells (Fig. 6). However, the swelling of the foot-
pads that received AC-SPL cells and anti-TGF-b antibodies
was not signiﬁcantly different from that of challenged immu-
nized mice that received PCl only or PCl and the isotype
control antibody MOPC 21. Similar results were obtained
when mice received unseparated AC-SPL cells 6 anti-TGF-b
antibody (data not shown).
Discussion
The injection of antigen into the AC generates circulating F4/
80
+ cells that migrate to the spleen and thymus (10, 24–26).
Thymic NKT cells, activated by these F4/80
+ cells migrate to
the spleen where, in concert with F4/80
+ cells, marginal zone
B cells and splenic NKT cells activate regulatory CD8
+
T cells (11). Whether these F4/80
+ cells were circulating cells
recruited to the AC and then recirculated or were resident in
the iris is not known. However, TGF-b in aqueous humor
and/or produced by iris F4/80
+ cells induces a suppressive
phenotype in F4/80
+ cells (25). Therefore, we investigated
whether TGF-b is required directly by T cells in vivo for the
generation of splenic CD8
+ regulatory T cells after the
Fig. 4. DTH in Cbl-b
/ mice is resistant to suppression by WT-AC-
SPL cells. Twenty-ﬁve thousand AC-SPL cells from WT (C57BL/6),
Cbl-b
+/+ mice that received intracameral TNP–BSA were injected into
footpads intradermally immediately after the footpads of TNP–BSA-
immunized Cbl-b
/ and WT mice were challenged with epicuta-
neous PCl. Swelling was measured 24 h after challenge. Data
represent the pooled results of three experiments and are the mean
swelling 6 SEM of 8–9 mice per group. *P < 0.03. NAIVE, non-
immunized; IMM, immunized.
Fig. 5. DTH in dnTGFbRII mice is resistant to suppression by WT-AC-
SPL cells. Twenty-ﬁve thousand AC-SPL cells from C57BL/6 mice that
received intracameral TNP–BSA were injected into footpads in-
tradermally immediately after the footpads of TNP–BSA-immunized
dnTGFbRII mice or WT mice were challenged with epicutaneous PCl.
Swelling was measured 24 h after challenge. The data represent the
pooled mean swelling 6 SEM of 9–10 mice per group in three
experiments. *P < 0.02. Immunized: immunized, challenged mice;
NAIVE: swelling in challenged, non-immunized mice. NAIVE, non-
immunized; IMM, immunized.
Fig. 6. Anti-TGF-b antibodies inhibit the suppressive activity of AC-
SPL cells in the LTS. WT mice were immunized with TNP–BSA 1 week
after they received an intracameral injection of TNP–BSA. One week
after immunizing, spleen cell suspensions were prepared. The cell
suspensions were incubated for 30 min at 4 C. in PBS, PBS + 15 lg
anti-TGF-b 1–3 antibodies or control MOPC 21 IgG1 antibody. After
incubation, the cells 6 antibodies or anti-TGF-b antibody only were
injected into footpads of TNP–BSA-immunized recipients immediately
after the footpad received an epicutaneous challenge with PCl.
Swelling was measured 24 h later. Data represent the mean swelling 6
SEM of six mice per group pooled from two experiments. *P < 0.01.
NAIVE, non-immunized; IMM, immunized.
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+ Treg 571injection of antigen into the AC. Although unseparated
dnTGFbRII and Cbl-b
/ AC-SPL cells did not suppress the
DTH reaction when injected into the footpads of immunized
mice immediately after antigenic challenge, CD8
+ AC-SPL
cells enriched from the unseparated cell population sup-
pressed the DTH response (Fig. 3A and B). The unsepa-
rated cell population could contain CD4
+-sensitized T cells
resistant to TGF-b-mediated suppression that would transfer
the DTH reaction to the sensitized recipients. Because
Cbl-b
/ and dnTGFbRII mice produce CD8
+ regulatory
AC-SPL cells, the generation of circulating F4/80
+ cells and
regulatory thymocytes is also intact (data not shown). We
have observed that the spleens of dnTGFbRII mice receiving
intracameral antigen and immunization contain different
numbers of DTH-inducing T cells and CD8
+ regulatory T cells
such that each cell population can be demonstrated when
transferring higher or lower numbers of cells (R. E. Cone
and Y. Lemire, unpublished observations). TGF-b can ‘con-
vert’ activated CD8
+ T cells to a suppressive phenotype
in vitro (15). Therefore, our results do not preclude a direct
role for TGF-b in the in vivo generation of CD8
+ regulatory
T cells after the intracameral injection of antigen. In particu-
lar, if some circulating CD8
+ regulatory T cells migrate to the
AC perhaps they will be ‘converted’ to regulatory T cells in
the AC by TGF-b in the aqueous humor. However, F4/80
+
cells in the AC likely have a suppressive phenotype due to
the TGF-b in aqueous humor and are central to the induction
of peripheral regulatory T cells.
CD8
+ regulatory T cells, unlike CD4
+, CD25
+ FoxP3
+ regu-
latory T cells suppress activated T cells (1–3, 7). Moreover,
CD8
+ regulatory T cells are detected after immunization and
there is no evidence at present for naturally occurring CD8
+
regulatory T cells. Unlike CD4
+ Treg, the suppression
effected by CD8
+ Treg is highly antigen speciﬁc (1, 2) and
may be directed toward TCR V-region epitopes (1, 5). Like
CD4
+ Treg, the suppressive mechanisms of CD8
+ regulatory
T cells have not been deﬁned. This issue is complicated by
the description of several types of CD8
+ regulatory T cells
that may suppress by distinct mechanisms (27–29). CD8
+
regulatory T cells can be induced in vivo (1–6) or in vitro
(15, 16). We chose to investigate a mechanism of suppres-
sion effected by CD8
+ regulatory T cells induced in vivo be-
cause it is well established that the injection of antigen into
the AC induces the production of antigen-speciﬁc, splenic
CD8
+ regulatory T cells that are capable of suppressing
a DTH reaction in sensitized recipients (6, 8–12, 26, 30). We
conﬁrmed that the suppression of the DTH reaction in the
LTS is speciﬁc to the antigen injected into the AC. CD8
 or
CD4
+ AC-SPL cells do not suppress the DTH reaction in the
LTS or the local adoptive transfer assay (8–10, 31). There-
fore, it is unlikely that CD4/CD25
+ T cells suppress the DTH
reaction in the LTS. However, intracamerally induced CD4
+
T cells induce CD8
+ regulatory T cells (23, 25, 32). Splenic
regulatory CD8
+ T cells are induced in vitro by TGF-b or
TGF-b, antigen-pulsed F4/80
+ cells (15, 16). CD8
+ regulatory
T cells are induced (converted?) in vitro by TGF-b, the
in vitro ligation of 4-1BB by anti-4-1BB antibodies (13, 14) or
the injection of antigen into the AC (12, 23) produce TGF-b.
Therefore, we asked whether TGF-b could be a mechanism
used by CD8
+ regulatory AC-SPL cells to mediate the sup-
pression of DTH. We determined whether the DTH reaction
is suppressed by CD8
+ AC-SPL cells in the presence of anti-
bodies to TGF-b or whether the DTH reaction in immunized
mice with T cells resistant to TGF-b is suppressed by CD8
+
AC-SPL cells in the LTS. Our observation of a complete inhi-
bition in vivo of the suppression of DTH to PCI by TNP-
speciﬁc–BSA-AC-SPL cells by antibodies to TGF-b isoforms
13 is similar to our observation of the anti-TGF-b-induced
inhibition of the suppression of OVA-induced DTH by OVA-
speciﬁc AC-SPL cells (33). The inhibition of CD8
+ AC-SPL
cell-mediated suppression of DTH is consistent with a report
that the DTH reaction is enhanced by antibodies to anti-
TGF-b injected into the immunized recipients at the site chal-
lenged with antigen to elicit a DTH reaction (34). Moreover,
we observed that two strains of mice, Cbl-b
/ and
dnTGFbRII, in which the T cells are resistant to TGF-b based
on different mechanisms, are also resistant to the suppres-
sion of the DTH reaction by CD8
+ AC-SPL cells. In one
strain, dnTGFbRII, there is a proximal defect in TGF-b signal-
ing in T cells resulting from the transgenic expression of
a dnTGFbRII (17, 22). In the second strain, Cbl-b
/ mice
have a normal receptor for TGF-b but the absence of the
ubiquitin ligase Cbl-b renders the cells incapable of
responding to TGF-b signaling (20, 21).
Although both strains may have immunological defects,
we show that the DTH response to immunization is similar
(or sometimes stronger) than that induced in a WT mouse.
In these studies, we did not generally use isolated splenic
CD8
+ cell populations to suppress a local DTH reaction be-
cause we demonstrated that CD8
+ but not CD4
+ splenic reg-
ulatory T cells induced by the injection of antigen into the AC
selectively suppress the in vivo DTH reaction (Fig. 1). More-
over, it is unlikely that the suppressive activity of the CD8
+
regulatory spleen cells induced by intracameral antigen is
mediated through cytotoxicity because in the LTS suppres-
sion of the DTH reaction by regulatory spleen cells is inde-
pendent of perforin and FasL (9).
Mice deﬁcient in Cbl-b have T cells that are CD28 inde-
pendent in their activation and hyperactive in their
responses (18–21). In addition, Cbl-b
/ mice develop spon-
taneous autoimmunity and have increased susceptibility to
elicited autoimmunity (18, 19). Although Cbl-b
/ mice have
normal numbers of functional CD4
+CD25
+ Foxp3
+ regulatory
T cells, their effector T cells are resistant to the suppression
mediated by both TGF-b and CD4
+CD25
+ Treg cells (20).
Cbl-b
/ effector T cells have been shown to express normal
levels of TGF-bRII, though an abnormality in Cbl-b
/ T cells
in the phosphorylation of Smad2 has been described (20).
In the present studies, we extended these ﬁndings and
demonstrate that Cbl-b
/ effector T cells are also resistant
in vivo to CD8
+ regulatory T cells.
Because the resistance of Cbl-b
/ mice to TGF-b is likely
due to the complexities of signaling dysfunction in these mice,
we also investigated TGF-b resistance in dnTGFbRII mice in
which the resistance to TGF-b is a result of a dominant nega-
tive TGF-b receptor II expressed speciﬁcally on T cells (16,
22). As with DTH effector cells in Cbl-b
/ mice, DTH effector
T cells in dnTGFbRII mice were resistant to suppression by
splenic CD8
+ regulatory spleen cells. That both strains, resis-
tant to TGF-b by completely different mechanisms, are
572 TGF-b and the in vivo induction/function of CD8
+ Tregresistant to the suppression effected by CD8
+ regulatory T cells
suggests that the resistance of the two strains to suppression
mediated by CD8
+ regulatory T cells has a common basis.
CD8
+ T (OT-1) cells converted to a suppressive phenotype
by culture with TGF-b and OVA suppressed the induction of
OVA-speciﬁc cytotoxic T cells in vitro and the rejection of
a cardiac allograft in mice transgenic for OVA by a TGF-b-
independent mechanism (15). Because the CD8
+ regulatory
T cells were induced by exposure to exogenous TGF-b and
antigen in vitro, they may differ from some CD8
+ regulatory
T cells induced in vivo. Different subtypes of CD8
+ regulatory
T cells have been described that function by distinct non-
lytic mechanisms (27, 28). Our results with antibodies to
TGF-b and the resistance of TGF-b-resistant mice to the sup-
pression of the DTH reaction by CD8
+ AC-SPL cells provide
evidence that TGF-b is an efferent suppressive mechanism
of these cells. However, the LTS assay measures the sup-
pression of DTH by a limited number of cells. It is possible
that the use of larger numbers of cells may reveal additional
suppressive mechanisms. Additionally, T cell-derived TGF-
b1 has pleiotropic effects and may promote Th17 cell differ-
entiation while suppressing Th1 cell differentiation (35, 36).
Our experiments have not identiﬁed the TGF-b isoforms re-
sponsible for immunosuppression by CD8
+ regulatory T cells
nor the induction of AC-induced F4/80
+ T cells required to in-
duce immunoregulatory thymocytes or splenic CD8
+ T cells.
Accordingly, the afferent and efferent roles for TGF-b in the
suppression of cell-mediated immunity induced by the intra-
cameral injection of antigen are likely dependent on the
complexity of the phenomenon under investigation.
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Abbreviations
AC anterior chamber
CS contact sensitivity
dnTGFbRII dominant negative receptor for transforming growth
factor b receptor type II
DTH delayed-type hypersensitivity
LTS local transfer of suppression
OVA ovalbumin
PCl picryl chloride
TGF transforming growth factor
TNP trinitrophenol
WT wild type
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